Clinical efficacy and tumour microenvironment influence of decitabine plus R‐CHOP in patients with newly diagnosed diffuse large B‐Cell lymphoma: Phase 1/2 and biomarker study-Reference-Cited by-全球学者库

Clinical efficacy and tumour microenvironment influence of decitabine plus R‐CHOP in patients with newly diagnosed diffuse large B‐Cell lymphoma: Phase 1/2 and biomarker study

Published:2021-12 Issue:12 Volume:11 Page:
ISSN:2001-1326
Container-title:Clinical and Translational Medicine
language:en
Short-container-title:Clinical & Translational Med

Author:

Zhang Mu‐Chen¹,Fang Ying¹²,Xu Peng‐Peng¹,Dong Lei³,Shen Rong¹,Huang Yao‐Hui¹,Fu Di¹,Yan Zi‐Xun¹,Cheng Shu¹,Jiang Xu‐Feng⁴,Song Qi⁵,He Yang¹,Zhao Yan¹,Lu Min¹,Ye Jing¹,Liu Feng¹,Cheng Lin¹,Wang Chao‐Fu³,Wang Li¹⁶,Zhao Wei‐Li¹⁶^ORCID

Affiliation:

1. Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China

2. Department of Hematology Shanghai Jiao Tong University Affiliated Sixth People's Hospital Shanghai China

3. Department of Pathology Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China

4. Department of Nuclear Medicine Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China

5. Department of Radiology Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine Shanghai China

6. Laboratory of Molecular Pathology Pôle de Recherches Sino‐Français en Science du Vivant et Génomique Shanghai China

Funder

National Natural Science Foundation of China

Samuel Waxman Cancer Research Foundation

Publisher

Wiley

Subject

Molecular Medicine,Medicine (miscellaneous)

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/ctm2.584

Reference11 articles.

1. Genetic alterations and their clinical implications in DLBCL

2. Anthracycline dose optimisation in patients with diffuse large B-cell lymphoma: a multicentre, phase 3, randomised, controlled trial

3. A perspective on improving the R-CHOP regimen: from Mega-CHOP to ROBUST R-CHOP, the PHOENIX is yet to rise

4. Immune dysregulation and multisystem inflammatory syndrome in children (MIS-C) in individuals with haploinsufficiency of SOCS1

5. Transcription factor IRF8 directs a silencing programme for TH17 cell differentiation

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. TP53 mutations predict for poor outcomes in patients with newly diagnosed aggressive B-cell lymphomas in the current era;Blood Advances;2023-11-30

2. Human endogenous retroviruses as epigenetic therapeutic targets in TP53-mutated diffuse large B-cell lymphoma;Signal Transduction and Targeted Therapy;2023-10-06

3. Genetic subtype-guided immunochemotherapy in diffuse large B cell lymphoma: The randomized GUIDANCE-01 trial;Cancer Cell;2023-10

4. Simplified algorithm for genetic subtyping in diffuse large B-cell lymphoma;Signal Transduction and Targeted Therapy;2023-04-10

5. Inhibitory effect and related mechanism of decitabine combined with gemcitabine on proliferation of NK/T cell lymphoma cells;Frontiers in Pharmacology;2023-03-01